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Background: The phosphoinositide 3- kinase (PI3K) pathway is involved in the growth of various human cancers,
including lymphoid malignancies. However its role in the pathogenesis of follicular lymphoma (FL) has not been
yet described.
Methods: To clarify this point, biopsy tissue samples from 38 human FL cases were investigated for PIK3CA somatic
mutations in exon 9 and 20 using direct sequencing. The same samples were analyzed using western blotting and
immunohistochemistry to detect expression of AKT, phosphorylated AKT (pAKT), and PTEN proteins. Two cases of
benign lymphadenitis were used as controls.
Results: AKT expression was present in all FL and lymphadenitis cases. 14/38 (37%) FL and 2/2 lymphadenitis cases
expressed pAKT. 9/38 (24%) FL samples showed high level of pAKT, whereas 5/38 (13%) FL cases and 2/2 benign
lymphadenitis samples expressed low level of pAKT. PTEN expression was observed in 30/38 (79%) FL and 2/2
benign lymphadenitis cases, whereas 8/38 (21%) FL cases showed loss of PTEN expression. 3 cases with positive
pAKT did not express PTEN. PIK3CA mutations were not detected in any sample.
Conclusions: These data suggest that the PI3K/AKT signaling pathway could be activated in a subset of FL cases,
due to either AKT phosphorylation or PTEN downregulation, in the absence of PIK3CA mutations.
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Follicular lymphoma is the most frequent occurring form
of low grade of Non Hodgkin lymphoma (NHL) and
account for approximately 20% of NHL cases [1]. The
clinical course of FL is relatively indolent when chemo-
therapeutic agents are combined with rituximab [2].
Nonetheless, a significant proportion of cases either
relapses or transform into aggressive diffuse large B cell
lymphomas (DLBCL) [2]. Thus there is a need for more
efficient therapies to improve the outcome of FL patients.
The use of immunomodulating agents has recently proved
to be of clinical interest [3]. Other targets related to FL
pathogenesis could offer new opportunities.
FL is derived from germinal center B cells and charac-
terized in most cases by the chromosomal translocation
t(14; 18) (q32; q21), causing deregulated expression of
the anti-apoptotic Bcl2 protein [1]. This translocation is* Correspondence: imene.yahiaoui@inserm.fr
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pathogenesis in the FL, but is not sufficient in the devel-
opment of FL [1]. Additional pathogenic events that are
required for the manifestation of FL remain poorly under-
stood. They may be related to molecular mechanisms
involved in the regulation of physiological process includ-
ing cell proliferation, survival, angiogenesis and tumor
growth, such as the PI3K/AKT/mTOR pathway [4,5].
PI3Ks are a family of lipid kinases classified into three
major subfamilies. The PI3K class I is activated by cell
surface receptors and consists of two subfamilies, class
IA and class IB, which are composed of heterodimers
of catalytic and regulatory subunits, identified as p110
(α, β, δ)/p85(α, β) and p110γ/p101 for class IA and
class IB, respectively [6,7]. Class II PI3Ks are monomeric
isoforms p110-like catalytic subunit that can be activated
by RTK, cytokine receptors, and integrin. The class III
includes heterodimeric enzymes composed of VPs34
catalytic and p150 adaptor PI3K subunits [6,7].
In response to growth factors, protein tyrosine kinases
receptors can recruit and activate PI3K, which in turnl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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trisphosphate (PIP3) levels. The phosphatase and tensin
homolog (PTEN) protein dephosphorylates PIP3 to
PIP2, acting as an antagonist of PI3K. PIP3 transduces
intracellular signaling by recruiting and participating to
the phosphorylation of variety of proteins including the
serine/threonine kinase AKT. Subsequently, activated
AKT may phosphorylate a range of substrates, thereby
activating these targets and favoring cell survival [8,9].
Constitutive activation of the PI3K/AKT pathway occurs
in various human cancers due to genetic aberrations. They
include mutation or amplification of the catalytic subunit
p110α encoded by PIK3CA gene [10-15], loss of PTEN
function through mutations, deletions, promoter methyla-
tion silencing, or protein instability [16,17]. Similarly, gain
of function of AKT can occur by amplification, overex-
pression, and increased phosphorylation [18-20], or muta-
tion of p85α regulatory subunit of PI3K [21,22]. Activating
mutations of PIK3CA p110α are among the most frequent
alterations in human cancers [23,24].
Only a few studies have reported dysregulation of the
PI3K/AKT pathway in lymphoid malignancies. PIK3CA
mutations and PTEN inactivation were detected in
DLBCLs, and high pAKT expression was associated with
poor survival [25,26]. Mantle cell lymphomas (MCL)
were shown to lack PIK3CA mutations, but often display
constitutive AKT activation, resulting from loss of PTEN
expression in some cases [27]. Loss of PTEN expression
and/or PIK3CA gene amplification were found to be
mutually exclusive mechanisms of AKT activation in the
pathogenesis of MCL [28].
FL tissue samples analyzed using proteomic analysis
showed increased expression of phosphorylated AKT at
the position Ser473 [29,30]. Besides, there is a relative
effectiveness of PI3K and mTOR inhibitors (NVP-BEZ235)
on human lymphoma cell lines [2].
Recently, idelalisib (CAL- 101), a PI3Kδ inhibitor was
shown to downregulate pAKT expression and to induce
apoptosis in FL cell lines [31], leading to a phase I study with
promising results in patients with Non Hodgkin Lymphoma
[32] that will be extended in phase II study [33]. Altogether
these previous works indicate that dysfunction of PI3K/AKT
pathway might be involved in the pathogenesis of FL by
some mechanisms that remain unclear to date.
In the present study, we have sought to better charac-
terize this putative PI3K/AKT dysfunction in a series of FL
tissue samples using a combination of methods including
DNA sequencing, western blot (WB) and immunohisto-
chemistry (IHC).
Methods
Tumor tissue samples and patients
Frozen tissue samples were collected between 2002 and
2012 from 38 FL patients at the time of diagnosis, priorto any treatment. Immunophenotyping at the time of
diagnosis showed that all FL cases contained more than
70% of tumor B cells (based on immunohistochemical
CD20 expression), whereas the reactive T-cell component
identified by CD3 positivity was lower than 30%. Two
benign lymphadenitis samples were used as controls. All
patients gave informed consent and the study was approved
by the ethical board of the Paoli-Calmettes institute.
The corresponding formalin fixed and paraffin embedded
samples were also available. The diagnosis of FL was made
according to the World Health Organization classification
[34], the FL samples were classified as grade 1-2 (n = 34),
grade 3 (n = 2) and not gradable (n = 2). The clinical char-
acteristics of the patients are detailed in Table 1. Median
follow-up of patients was 94 months.
DNA, RNA, and protein extraction
Genomic DNA, RNA, and proteins were extracted from
frozen tissues using AllPrep DNA/RNA/Protein purifi-
cation kit (QIAGEN) according to the manufacturer’s
protocol. The concentration and purity of DNA and RNA
of each sample were measured using a Nanodrop.
Polymerase Chain Reaction (PCR) and PIK3CA hotspot
mutations analysis
The PCR mixture contained 25 ng of DNA, 0.4 μM of
each primer (forward and reverse for exon 9 or 20, see
below for sequences), 0.2 mM of dNTP, 0.04 U of Taq
DNA polymerase, 1.5 mMMgCl2 in TE buffer. To amplify
exon 20, after an initial activation at 95°C for 10 minutes,
35 cycles were done, which include 30 seconds at 95°C for
denaturation step, 30 seconds for annealing step at 55°C
and 30 seconds for elongation step at 72°C.
Finally, termination step followed at 72°C for 10 minutes.
To amplify exon 9, a touch-down PCR was done to avoid
amplification of a non-specific PCR product. Activation,
denaturation, elongation and termination steps were the
same as exon 20 but annealing temperatures changed: 4
cycles at 60°C, 4 cycles at 59°C, 4 cycles at 58°C, 6 cycles at
57°C, 6 cycles at 56°C, 8 cycles at 55°C and 13 cycles at
54°C. PCR products were then separated by 2% agarose
gel electrophoresis to visualize the appropriate bands.
The PCR products were cleaned-up using a Multiscreen
plate (Millipore) according to the manufacturer’s proto-
col and subjected to sequencing reaction in forward
and reverse directions using ABI Big Dye Terminator
V1.1 and an ABI 3730 automated capillary sequencer
(Applied Biosystem). The data were analyzed with
SeqScape software. The primers used for PCR and
sequencing were as follows: exon 9, 5'-TTGCTTTTT
CTGTAAATCATCTGT-3' (forward) and 5'-CTGCTTTA
TTTATTCCAATAGGTATG-3' (reverse); exon 20, 5'-CT
CAATGATGCTTGGCTCTG-3' (forward) and 5'-GGAAT
CCAGAGTGAGCTTTC-3' (reverse).
Table 1 Clinical characteristics and pAKT expression status of FL patients
Negative pAKT Positive pAKT
Total n % n % P
NO, patients 36 22 61 14 39
Sex Male 10 45 6 43 0.577
Female 12 55 8 57
Age < 60 years 15 68 10 71 0.569
≥ 60 years 7 32 4 29
Median [range] 56 [30-72] 52 [34-68] 0.575
Lactate dehydrogenase N 19 86 8 57 0.03
>N 2 9 6 43
Unknown 1 5 0 0
Performance status 0 7 32 2 14 0.045
1 0 0 3 22
Unknown 15 68 9 64
B symptoms 0 5 23 4 29 0.601
1 4 18 4 29
Unknown 13 59 6 42
Ann Arabor stage I-II 7 32 2 14 0.254
III-IV 15 68 11 79
Unknown 0 0 1 7
Adenopathy 0-3 14 64 7 50 0.282
4 or more 6 27 6 43
Unknown 2 9 1 7
Hemoglobin ≥ 12 g/dl 13 59 9 64 0.684
< 12 g/dl 3 14 2 14
Unknown 6 27 3 22
β2 microglobulin N 9 41 5 36 0.306
> N 4 18 5 36
Unknown 9 41 4 28
Bone marrow involvement 0 9 41 7 50 0.58
1 10 45 7 50
Unknown 3 14 0 0
FLIPI 0-1 3 14 1 7 0.390
2 7 32 4 29
≥ 3 4 18 6 43
Unknown 8 36 3 21
Follow up (months) Median [range] 90 [9-200] 97 [50-200] 0.687
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Protein pellets were isolated after purification of gen-
omic DNA and RNA according to the manufacturer’s
instructions, and were then dissolved in 2 × Laemmli
buffer. Protein samples were heated at 95°C for 5 minutes
and resolved by standard 9% SDS-polyacrylamide gels.
Immunoblots were performed as previously described
[35]. The primary antibodies used are commercially avail-
able, anti- AKT (Cell Signaling Technology (CST), # 9272,used at 1:1800 dilution) anti- phospho Ser473-AKT (CST,
# 4058, used at 1:1000 dilution), anti- PTEN (CST, # 9552,
clone 138G6, used at 1:1000 dilution) and anti-GAPDH
(Abcam, clone mAbcam 9484, used at 1:5000 dilution).
These antibodies were used in TBS - 0.1% Tween 20 - 5%
BSA, overnight at 4°C under agitation. Lysates from the
Jurkat (loss of PTEN) and SupT1 (PTEN-positive) T cell
lines were used as positive and negative controls for AKT
phosphorylation, and PTEN expression, respectively.
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evaluate the expression of phosphorylated form of AKT
(pAKT) in each sample. The same method was used to
evaluate PTEN expression, except that GAPDH was
used as an additional loading control.
Densitometric analysis of AKT and pSer473-AKT bands
were quantified using ImageJ software and the ratio
pSer473-AKT/AKT values of each sample were normalized
to the value of Jurkat cell condition as positive control.
Immunohistochemistry
4 μm paraffin sections were cut, mounted on glass slides
and air dried overnight at room temperature. The staining
protocol was performed using an Envision FLEX/Dako
Autostainer system according to the manufacturer’s sup-
plied instructions (Dako, Glostrup, Denmark). Antigen
retrieval was accomplished by heating the slides in
EnVision FLEX target retrieval solution pH 6 (Dako) at
99°C for 40 minutes. The slides were cooled down at
room temperature for 20 minutes, washed for 5 minutes
in the EnVision FLEX wash buffer. Endogenous peroxid-
ase activity and non-specific binding sites were blocked
with EnVision FLEX Peroxidase-Blocking Reagent (Dako)
for 5 minutes. The slides were then washed with EnVision
FLEX wash buffer, then incubated with either the mouse
mAb anti-pSer473-AKT (CST, # 4051, clone 587 F11,
used at 1:200 dilution), or with the mouse mAb anti-
PTEN (Dako, clone 6H2.1, used at 1:150 dilution) at room
temperature for 60 minutes, followed by washing in the
EnVision FLEX wash buffer.
To obtain an optimal amplification of the PTEN staining,
slides were incubated with the EnVision FLEX Mouse
LINKER (Dako) for 15 minutes. After washing, immuno-
detection was achieved using Envision FLEX system
[EnVision FLEX HRP for 20 minutes, followed by incuba-
tion in the EnVision FLEX DAB + Chromogen solution
(3, 3’-diaminobenzidine tetrahydrochloride, Dako) for
10 minutes], rinsed with EnVision FLEX wash buffer to
remove residue 3, 3'-diaminobenzidine tetrahydrochloride,
counterstained with EnVision FLEX Hematoxylin for
5 minutes. Positive controls were breast tumors express-
ing pAKTand normal uterus samples expressing PTEN.
Statistical analysis
The association of pAKT expression with patient’s char-
acteristics was performed using chi-squared (x2) tests for
categorical data. Overall survival (OS) was measured
from date of diagnosis to date of death or until the date
of last follow up visit for alive patients. Progression free
survival (PFS) was defined as the response time after the
first chemotherapy. Survival analysis was carried out using
Kaplan-Meier method and the log rank test was used
when comparing groups. Statistical data was produced by
the software SPSS.Results
Absence of activating mutation of the PIK3CA gene in FL
Mutational analysis of the somatic mutations within
exon 9 and 20 of PIK3CA was done to assess the two
hotspots regions in the helical (exon 9) and kinase (exon
20) domains, in which 80% of the reported mutations
are found [10]. We did not detect any mutations in our
38 FL cases.
Expression of AKT, activated AKT, and PTEN in FL
Western blot
To investigate the activation status of PI3K/AKT path-
way in follicular lymphoma, we assessed the expression
of AKT and phosphorylated AKT (Ser473), and PTEN
protein expression level using WB and IHC. WB analysis
revealed in all 38 FL frozen samples a 60 kDa band eviden-
cing AKT expression. Expression of pAKT was observed in
14/38 (37%) FL samples (Figure 1A) at a similar molecular
weight of 60 kDa.
Densitometric measurement of the relative intensity of
pAKT bands categorizes our series into three groups: 9/
38 (24%) FL cases with high level of pAKT protein, 5/38
(13%) FL cases with low level of pAKT protein, and 24/38
(63%) FL cases negative for pAKT expression (Figure 2).
In the positive control (Jurkat cells) and negative control
(SupT1 cells), the relative value of pAKT protein was
considered as 1, and 0.04, respectively. It was estimated
between 0.83 and 1.25 for the FL group with high
pAKT expression level. In comparison the value was
evaluated between 0.31 and 0.56 in FLs with low pAKT
level, and between 0.01 and 0.28 in the negative pAKT
expression group (Figure 2).
To further study the mechanisms of AKT activation in
FL, we evaluated PTEN profile expression in the same
samples. WB analysis showed that 30/38 (79%) FL
expressed PTEN at 54 kDa, whereas 8/38 (21%) of cases
showed no expression of PTEN (Figure 1A). Of the 8
cases with loss of PTEN, only 3 were associated with
pAKT expression, including 2 cases (cases #31 and #32)
with high level of AKT activation, and 1 case (case #30)
with low level of AKT activation (Figure 1A), whereas 5
of the 8 cases with loss of PTEN had no pAKT expres-
sion. Loss of PTEN and the absence of serine phosphor-
ylation of AKT at the position 473 (pAKT) in these 5
cases were further validated in an independent WB ana-
lysis, in which GAPDH was used as a loading control
(Figure 1B).
Eleven out of 14 FL cases with positive pAKT expressed
PTEN. WB showed expression of AKT and PTEN pro-
teins in the lymphadenitis samples (cases #39 and #40)
(Figure 1A), which also expressed phosphorylated AKT
at low level. Relative value of pAKT was estimated as
0.48 and 0.56 for case #39 and case #40, respectively
(Figure 2).
Figure 1 Representative western blot analysis of AKT, activated AKTSer473, and PTEN in 38 FL samples (#1-38) and lymphadenitis
cases (#39 and #40). AKT was detected in all examined samples, and is shown as a loading control for pAKT detection (panel A). GAPDH is also
used as a loading control for PTEN detection (panel B). Asterisks indicate positive samples for pAKT; pAKT expression was detected at high level
in samples #6, #7, #9, #13, #14, #29, #31, #32, and #38; and at low level in samples #4, #8, #12, #20, #30, #39, and #40. Jurkat cells served as a
positive control for pAKT expression. SupT1 cells served as a positive control for PTEN expression. These results shown are representative of 3
independent experiments.
Figure 2 Quantification of relative p-Ser473 AKT (pAKT) protein amount in FL samples (#1-38) and lymphadenitis cases (#39 and #40).
Samples are ordered according to their p-Ser473AKT level of expression (values are indicated above each bar). The numbering of samples is similar to
Figure 1. Jurkat (positive control) and SupT1 (negative control) correspond to the expected profile.
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The expression of pAKT and PTEN was examined using
immunohistochemistry in the corresponding paraffin-
embedded FL samples. Positive pAKT immunostaining
of variable intensity was observed in intra-follicular ma-
lignant B-cells from 15/38 FL samples (Figure 3A).
Among these 15 cases, rare interfollicular reactive
T-cells showed positive pAKT staining in one case. 18/38
FL specimens were negative for pAKT staining, whereas
the IHC status could not be assessed in 5 specimens.
PTEN immunostaining was positive in malignant
intra-follicular B-cells in 30/38 cases, and 18 out of these
30 samples also displayed the same intensity of PTEN
positivity in reactive interfollicular T-cells and macro-
phages. PTEN signals were heterogeneous in 12 out of
these 30 samples, displaying either strong PTEN positivity
in malignant B-cell follicles associated with low staining of
reactive T-cells and macrophages around the follicles, or
an inverse profile of positivity (Figure 3B and C). PTENFigure 3 Representative images of immunohistochemical staining of
pAKT staining in lymphoma cells (arrows) (magnification is × 40 and × 630
lymphoma cells (arrows) within the malignant follicles (stars) (magnification
positivity of PTEN around follicles (arrows) with weak expression in lympho
(arrowheads) (magnification is × 40 and × 630 for the left and right panels,staining was negative in 3/38 specimens, whereas the IHC
status could not be assessed in 5 specimens.
The benign lymphadenitis cases showed homogeneous
positive staining of PTEN. For the pAKT staining, case
#39 had rare positive cells, and case #40 showed nega-
tive staining of pAKT.
Correlations between IHC and WB
The 8 PTEN WB-negative cases showed different pat-
tern of IHC expression: 1 case was completely negative;
one case was not evaluable due to high background,
whereas the other cases showed heterogeneous expres-
sion in a fraction of malignant or reactive cells.
Although IHC data correlated with WB results in most
samples, it is noteworthy that the correlation was not
perfect. This may be due to the different levels of sensitiv-
ity of each method and/or to the intra-tumoral heterogen-
eity. In this extent, WB appeared more reliable to evaluate
the level of pAKTand PTEN expression because it reflectspAKT and PTEN in FL samples. (A) Strong nuclear and cytoplasmic
for the left and right panels, respectively). (B) Strong PTEN staining in
is × 40 and × 630 for the left and right panels, respectively). (C) Strong
ma cells within the follicles (stars), reactive T cells are positive
respectively).
Table 2 Summary of western blot analysis of AKT, pAKT,
and PTEN expression
Samples AKT expression pAKT expression PTEN expression
1 + - +
2 + - +
3 + - +
4 + + +
5 + - +
6 + + +
7 + + +
8 + + +
9 + + +
10 + - -
11 + - +
12 + + +
13 + + +
14 + + +
15 + - +
16 + - +
17 + - -
18 + - +
19 + - +
20 + + +
21 + - +
22 + - +
23 + - +
24 + - +
25 + - +
26 + - -
27 + - +
28 + - +
29 + + +
30 + + -
31 + + -
32 + + -
33 + - -
34 + - +
35 + - +
36 + - -
37 + - +
38 + + +
39 + + +
40 + + +
Follicular Lymphoma samples (#1-38); lymphadenitis samples (#39 and 40).All
samples are wild type for the mutation of PIK3CA gene. +: expression; -: no
expression.
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quantified using densitometry. In contrast, it was not pos-
sible to assess a reliable positive cut-off for IHC expression
due to the variations in the number of positive cells within
sections. However, IHC was useful and necessary to
localize the expression in malignant and /or reactive cells.
The results are summarized in Table 2.
Correlation with clinical features
We were interested in testing the relationship between
pAKT expression status and clinicopathological parame-
ters like histological grade, tumor volume, overall sur-
vival (OS), and progression free survival (PFS). No
significant correlations were found with any parameters.
The clinical features of patients are summarized in
Table 1.
Discussion
The PI3K/AKT pathway is frequently activated in hu-
man carcinomas by oncogenic mutations of the PIK3CA
gene encoding for the α isoform of the PI3K p110 sub-
unit (24). Only a few studies have focused on the PI3K/
AKT pathway in lymphoid neoplasms. It was reported to
be activated in DLBCL [25,26] and MCL [27,28] due to
the presence of phosphorylated AKT (Ser473). As to FL,
an increase of phosphorylated AKT (Ser473) has also
been shown in two different reports using a proteomic
approach by laser capture microdissection and reverse
phase protein microarray, but the mutational status of
PI3K was not addressed [29,30]. Due to the scarcity of
data in the literature, we aimed in the present study to
further clarify the abnormalities of the PI3K/AKT path-
way in FL.
We could detect phosphorylation of AKT using WB in
37% of FL samples, most of them displaying high level
of pAKT expression. This finding is in accordance with
those previously obtained using a reverse phase protein
microarray approach [29,30], suggesting that activation
of the PI3K/AKT pathway might contribute in the devel-
opment of FL.
Of note, correlations between WB and IHC data were
not strictly correlated, probably due to the visual scoring
used for IHC analysis, which resulted in less accurate
quantification than the automatic densitometry method
used for WB analysis. This may be also explained by the
requirement of different antibodies and by the different
threshold levels of sensitivity in each method. WB re-
sults were considered for subsequent statistical and clin-
ical correlations because the intra-tumoral heterogeneity
can account for a biased pattern of IHC expression in a
single tissue section, whereas WB is more likely to ac-
curately reflect a given level of protein expression in the
whole tissue sample. IHC was however useful to confirm
that pAKT and PTEN expression were located in
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relations of pAKT WB expression with clinicopathologi-
cal data, but this could be attributed to the relatively
small number of cases in our series.
Aberrant regulation of the PI3K/AKT signaling pathway
in MCL occurs most frequently by loss of PTEN expression
and/or PIK3CA gene amplification, whereas the PIK3CA
gene was found unmutated [27,28]. Similarly, no activat-
ing mutations of PIK3CA gene have been identified in our
series of FL. Since we analyzed only hot spot loci in both
the helical and kinase domains, we cannot rule out the
hypothesis that some mutations could be located in other
domains. This seems unlikely since the hot spot loci are
common to a wide variety of human tumors [10,11,23,36].
Altogether, these results suggest that PIK3CA muta-
tions are not a frequent AKT activating mechanism in
lymphoid neoplasm. We have thus searched for another
mechanism of AKT activation. In our cohort, we found
loss of PTEN in 3 cases with activated AKT, including 2
cases with a high level of pAKT expression. However
only a minority of pAKT activated FL samples displayed
loss of PTEN, which argues against a crucial role of
PTEN dysfunction in FL pathogenesis. Activation of
PI3K/AKT pathway may thus occur in FL through alter-
native events previously evidenced in other cancer types,
including mutation or gene amplification of membrane
receptors, overexpression of growth factors, AKT gene
amplification, and PIK3CA gene amplification [37,38,18].
The latter abnormality has been demonstrated in MCL
as an additional mechanism of AKT activation [28]. As
to FL, AKT activation may also be related to PI3Kδ. Al-
though no mutation of PI3Kδ was previously found [39],
it is expressed at high levels in lymphocytes and lymph-
oid tissue [40], and is involved in the survival of B cells
[41]. It will be interesting to further analyze phosphoryl-
ation events in FL patient samples at the single cell level
using detection of phospho-epitopes like phosphoflow
analysis [42].
Of note, loss of PTEN expression was also observed in
5 samples lacking pAKT expression. This suggests that
loss of PTEN expression may arise in FL without subse-
quent AKT activation. This may be related to negative
regulation of AKT by direct dephosphorylation of the
hydrophobic motif by the phosphatase PHLPP [43].
Conclusions
The present report suggests that the PI3K/AKT pathway
may be constitutively activated in some FL cases in the
absence of PIK3CA mutation. However, since these ab-
normalities were detected in only a fraction of FL cases,
they may be not sufficient to explain previous observa-
tions that a dual PI3K and mTOR inhibitor (NVP-
BEZ235) has a potential efficiency against FL cell lines
[2] and that the PI3Kδ inhibitor idelalisib (CAL- 101)has clinical activity against FL [31-33]. Further studies
are thus needed to better understand the mechanisms
involved by drugs targeting AKT and PI3K in FL.
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